Graeme Griffin
Overview
Explore the profile of Graeme Griffin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley J, et al.
Mol Cancer Ther
. 2006 Nov;
5(11):2676-84.
PMID: 17121914
The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers. One important signaling pathway regulated by EGFR is the phosphatidylinositol 3'-kinase (PI3K)-phosphoinositide-dependent kinase 1-Akt pathway. Activation of Akt...
2.
Overton H, Babbs A, Doel S, Fyfe M, Gardner L, Griffin G, et al.
Cell Metab
. 2006 Mar;
3(3):167-75.
PMID: 16517404
The endogenous lipid signaling agent oleoylethanolamide (OEA) has recently been described as a peripherally acting agent that reduces food intake and body weight gain in rat feeding models. This paper...
3.
Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al.
Cancer Res
. 2005 Oct;
65(20):9455-62.
PMID: 16230409
Treatment of second- and third-line patients with non-small-cell lung carcinoma (NSCLC) with the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib significantly increased survival relative to placebo. Whereas patient tumors...
4.
Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, et al.
Mol Cell Proteomics
. 2005 Jan;
4(4):356-76.
PMID: 15657067
Overexpression and enhanced activation of the epidermal growth factor (EGF) receptor are frequent events in human cancers that correlate with poor prognosis. Anti-phosphotyrosine and anti-EGFr affinity chromatography, isotope-coded muLC-MS/MS, and...
5.
Bass C, Griffin G, Grier M, Mahadevan A, Razdan R, Martin B
Pharmacol Biochem Behav
. 2002 Oct;
74(1):31-40.
PMID: 12376150
The central cannabinoid receptor (CB(1)) antagonist, SR-141716A, has been used extensively to ascertain that cannabinoids interact with the CB(1) receptor. SR-141716A has been shown to produce effects opposite of cannabinoids...
6.
Wiley J, Jefferson R, Griffin G, Liddle J, Yu S, Huffman J, et al.
Pharmacology
. 2002 Sep;
66(2):89-99.
PMID: 12207116
The present study investigated the role of peripheral cannabinoid (CB(2)) receptors in producing hypomobility, antinociception and hypothermia in mice. Results revealed that the CB(2)-selective antagonist, SR144528, did not block cannabimimetic...
7.
Lichtman A, Hawkins E, Griffin G, Cravatt B
J Pharmacol Exp Ther
. 2002 Jun;
302(1):73-9.
PMID: 12065702
Fatty acid amides (FAAs) represent a class of neuromodulatory lipids that includes the endocannabinoid anandamide and the sleep-inducing substance oleamide. Both anandamide and oleamide produce behavioral effects indicative of cannabinoid...
8.
Di Marzo V, Griffin G, De Petrocellis L, Brandi I, Bisogno T, Williams W, et al.
J Pharmacol Exp Ther
. 2002 Feb;
300(3):984-91.
PMID: 11861807
Arvanil, a structural "hybrid" between the endogenous cannabinoid CB1 receptor ligand anandamide and capsaicin, is a potent agonist for the capsaicin receptor VR1 (vanilloid receptor type 1), inhibits the anandamide...